Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000
Rhea-AI Filing Summary
Editas Medicine, Inc. reported that director Ellinor Patrick Thomas II received a grant of stock options covering 103400 shares of common stock. The options have an exercise price of $2.9000 per share, expire on 2036-08-05, and vest in three equal annual installments from 2027-08-06 through 2029-08-06. Following the grant, the director holds 103400 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ellinor Patrick Thomas II
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 103,400 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 103,400 shares (Direct)
Footnotes (1)
- F1. This option was granted on August 6, 2026 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on August 6, 2027 through August 6, 2029.
Key Figures
Options Granted: 103400 shares
Exercise Price: $2.9000 per share
Expiration Date: 2036-08-05
+2 more
5 metrics
Options Granted
103400 shares
Stock Option (right to buy) granted to director Ellinor Patrick Thomas II
Exercise Price
$2.9000 per share
Conversion or exercise price of the granted stock options
Expiration Date
2036-08-05
Scheduled expiration date of the stock option grant
Underlying Shares
103400 shares
Underlying common stock tied to the stock option grant
Post-Grant Holdings
103400 derivative securities
Total derivative securities held directly after the reported grant
Key Terms
Stock Option (right to buy), conversion or exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"Security title is listed as "Stock Option (right to buy)" for the derivative grant."
conversion or exercise price financial
"The option has a conversion or exercise price of 2.9000 per share."
vesting financial
"The option is scheduled to vest over three years in equal yearly installments."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The reported expiration date of the stock option grant is 2036-08-05."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"The underlying security title for the option is listed as Common Stock."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Editas Medicine (EDIT) disclose for Ellinor Patrick Thomas II?
Editas Medicine disclosed a grant of stock options to director Ellinor Patrick Thomas II for 103400 shares of common stock. These are derivative securities, not an open-market purchase or sale, and represent a compensation-related award rather than a cash transaction.
What is the exercise price of the new Editas Medicine (EDIT) stock options?
The granted stock options have an exercise price of $2.9000 per share. This is the price the director would pay to acquire each underlying share of Editas Medicine common stock upon exercising the options, once the relevant portion has vested.
When do the Editas Medicine (EDIT) options granted to the director vest?
The options are scheduled to vest over three years in equal yearly installments. One-third of the shares vest on 2027-08-06, another third on 2028-08-06, and the final third on 2029-08-06, assuming continued service through each vesting date.
What is the expiration date of the Editas Medicine (EDIT) stock options granted?
The stock options granted to the director are scheduled to expire on 2036-08-05. After this expiration date, any unexercised portion of the options will no longer be exercisable, regardless of whether it had previously vested.
How many Editas Medicine (EDIT) derivative securities does the director hold after this grant?
Following the reported grant, the director is shown as directly holding 103400 derivative securities. These represent stock options tied to Editas Medicine common stock, and this figure reflects the total after the new award.